Top Ten most popular articles on this week

pharmafile | March 2, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines 

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the EMA has followed suit with the FDA by announcing changes to the way new drugs will be tested in clinical trials.

In one of the biggest stories that broke towards the end of the year, Allergan finally found out whether its patent deal with a Native American tribe was enough to convince the courts to back off its patents on Restasis.

Check out the week’s ten most popular articles on here:

10.UK governmentt report looks to reduce vaccination spending

One of the largest petitions ever to have gone before UK parliament, after it attracted 823,349 signatures, brought about the eventual publication of a report into how vaccines are funded.

9. Takeda to create 70 jobs with €25m Dublin investment

Takeda announced the investment of €25 million to construct a new “modular cell therapy facility dedicated to manufacturing a novel stem cell therapy” at Grange Castle in Dublin and will create up to 70 new jobs in the process.

8. Mylan looks to muscle in on Allergan’s Botox territory

Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner on a Botox biosimilar.

7. Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod

Bavencio finally received some good news following the recommendation from NICE for its use in metastatic Merkel cell carcinoma, with it receiving funding from the Cancer Drug Fund.

6. EMA set to also revise guidelines of Alzheimer’s trials

The EMA, following on from the FDA’s lead earlier this month, announced that it will revise its guidelines on clinical trial studies for the treatment of Alzheimer’s disease from 1 September 2018 onwards.

5. FDA refuses to review Celgene’s ozanimod in multiple sclerosis

Celgene has revealed that the FDA rejected its New Drug Application for ozanimod in the treatment of relapsing forms of multiple sclerosis.

4. Europe approves first therapy for haemophilia A with inhibitors in over 20 years

Roche revealed that Hemlibra was approved by the European Commission for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.

3. AstraZeneca creates biotech spin-off, $250m in bank

Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely the case for Viela Bio after its creation from AZ.

2. Ipsen: Becoming a “development powerhouse”

Immediately following the release of impressive full year financials, Ipsen CEO David Meek spoke exclusively to on how the company is hitting its stride, with an ambitious outlook to grow its product offering in the coming years.

1. Allergan’s patent gamble fails

Allergan’s patent deal with the Saint Regis Mohawk Tribe, an attempt to protect itself from an inter partes review on Restasis, drew a huge number of headlines, mostly condemnatory; the judgement was passed as to whether this manoeuvre was valid and it wasn’t positive for Allergan.

Related Content

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

FDA approves ANDA of 20mg generic Nitisinone capsules

Analog Pharma and Dipharma have announced that the US Food and Drug Administration (FDA) has …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Latest content